A drug to slow progression in PPMS (and RRMS)

Everyday living
1

Here’s news of a big (phase III) trial showing that ocrelizumab (anti-CD20) slows acquisition of disability in PPMS and RRMS. I want to be on this drug.

http://multiple-sclerosis-research.blogspot.com/2015/09/newsspeak-finally-some-good-news-for.html

1 Like
2

OH yeh! I do hope you get it darlin!

luv Pollx

3

Now all we have to wait for is licensing … and NICE approval … and all our neurologists to get on board with it … and the setting up of prescribing centres … and training of MS nurses … So it should only take another few years then!!!

But still, excellent news at last.

Sue